These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 827770)

  • 1. Dopamine receptor alteration in schizophrenia: neuroendocrine evidence.
    Rotrosen J; Angrist BM; Gershon S; Sachar EJ; Halpern FS
    Psychopharmacology (Berl); 1976 Dec; 51(1):1-7. PubMed ID: 827770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine effects of apomorphine: characterization of response patterns and application to schizophrenia research.
    Rotrosen J; Angrist B; Gershon S; Paquin J; Branchey L; Oleshansky M; Halpern F; Sachar EJ
    Br J Psychiatry; 1979 Nov; 135():444-56. PubMed ID: 540209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of central dopamine receptors in schizophrenia.
    Zemlan FP; Hitzemann RJ; Hirschowitz J; Garver DL
    Am J Psychiatry; 1985 Nov; 142(11):1334-7. PubMed ID: 2865903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroendocrine studies with dopamine agonists in schizophrenia.
    Rotrosen J; Angrist B; Paquin J
    Psychopharmacol Bull; 1978 Jan; 14(1):14-7. PubMed ID: 625529
    [No Abstract]   [Full Text] [Related]  

  • 5. Apomorphine and schizophrenia. Treatment, CSF, and neuroendocrine responses.
    Levy MI; Davis BM; Mohs RC; Kendler KS; Mathé AA; Trigos G; Horvath TB; Davis KL
    Arch Gen Psychiatry; 1984 May; 41(5):520-4. PubMed ID: 6372737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
    Meltzer HY; Lee MA; Jayathilake K
    Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of prolactin by dopamine agonists in schizophrenics and controls.
    Rotrosen J; Angrist B; Clark C; Gershon S; Halpers FS; Sachar EJ
    Am J Psychiatry; 1978 Aug; 135(8):949-51. PubMed ID: 665840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of apomorphine on growth hormone and prolactin secretion in schizophrenic patients, with or without oral dyskinesia, withdrawn from chronic neuroleptic therapy.
    Ettigi P; Nair NP; Lal S; Cervantes P; Guyda H
    J Neurol Neurosurg Psychiatry; 1976 Sep; 39(9):870-6. PubMed ID: 993808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroendocrine aspects in monitoring of dopaminergic drugs in man.
    Hietala J; Koulu M; Scheinin M; Syvälahti E
    Methods Find Exp Clin Pharmacol; 1985 Aug; 7(8):451-4. PubMed ID: 3935892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postsynaptic supersensitivity in schizophrenia.
    Pandey GN; Garver DL; Tamminga C; Ericksen S; Ali SI; Davis JM
    Am J Psychiatry; 1977 May; 134(5):518-22. PubMed ID: 848578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dopaminergic function in two patients with catalepsy.
    Cervantes P; Lal S; Smith F; Guyda H
    Acta Psychiatr Scand; 1977 Mar; 55(3):214-9. PubMed ID: 848340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone response to placebo, apomorphine and growth hormone releasing hormone in abstinent alcoholics and control subjects.
    Wiesbeck GA; Mueller T; Wodarz N; Davids E; Kraus T; Thome J; Weijers HG; Boening J
    Drug Alcohol Depend; 1998 Sep; 52(1):53-6. PubMed ID: 9788006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A neuroendocrine study of supersensitivity in tardive dyskinesia.
    Tamminga CA; Smith RC; Pandey G; Frohman LA; Davis JM
    Arch Gen Psychiatry; 1977 Oct; 34(10):1199-203. PubMed ID: 911219
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of L-DOPA on nigral dopamine neurons and local field potential: comparison with apomorphine and muscimol.
    Xu D; Karain B; Brantley E; Shi WX
    J Pharmacol Exp Ther; 2011 May; 337(2):533-9. PubMed ID: 21330359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychopathological correlates of reduced dopamine receptor sensitivity in depression, schizophrenia, and opiate and alcohol dependence.
    Schmidt K; Nolte-Zenker B; Patzer J; Bauer M; Schmidt LG; Heinz A
    Pharmacopsychiatry; 2001 Mar; 34(2):66-72. PubMed ID: 11302566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroendocrine assessment of dopaminergic activity in schizophrenia.
    Rotrosen J; Angrist BM; Gershon S; Sachar EJ; Halpern FS
    Adv Biochem Psychopharmacol; 1977; 16():649-53. PubMed ID: 883563
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of apomorphine on blood levels of homovanillic acid, growth hormone and prolactin in medicated schizophrenics and healthy control subjects.
    Scheinin M; Syvälahti EK; Hietala J; Huupponen R; Pihlajamäki K; Seppälä OP; Säkö E
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(4):441-9. PubMed ID: 2866563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hormonal effects of apomorphine in schizophrenia.
    Ferrier IN; Johnstone EC; Crow TJ
    Br J Psychiatry; 1984 Apr; 144():349-57. PubMed ID: 6722395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems.
    Davis BM; Davis KL; Mohs RC; Mathé AA; Rothpearl AB; Johns CA; Levy MI; Horvath TB
    Arch Gen Psychiatry; 1985 Mar; 42(3):259-64. PubMed ID: 3977547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schneider's first-rank symptoms of schizophrenia. An association with increased growth hormone response to apomorphine.
    Whalley LJ; Christie JE; Brown S; Arbuthnott GW
    Arch Gen Psychiatry; 1984 Nov; 41(11):1040-3. PubMed ID: 6497565
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.